1. Home
  2. SPRO vs BHR Comparison

SPRO vs BHR Comparison

Compare SPRO & BHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$1.20

Market Cap

156.3M

Sector

Health Care

ML Signal

HOLD

BHR

Braemar Hotels & Resorts Inc.

HOLD

Current Price

$2.33

Market Cap

159.3M

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPRO
BHR
Founded
2013
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
156.3M
159.3M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
SPRO
BHR
Price
$1.20
$2.33
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
2.0M
662.9K
Earning Date
05-13-2026
05-06-2026
Dividend Yield
N/A
8.47%
EPS Growth
111.81
N/A
EPS
N/A
N/A
Revenue
$66,802,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$300.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
39.24
N/A
52 Week Low
$1.08
$1.88
52 Week High
$3.08
$3.19

Technical Indicators

Market Signals
Indicator
SPRO
BHR
Relative Strength Index (RSI) 22.37 62.04
Support Level N/A $2.19
Resistance Level $2.44 $2.61
Average True Range (ATR) 0.16 0.09
MACD -0.05 0.04
Stochastic Oscillator 10.32 88.75

Price Performance

Historical Comparison
SPRO
BHR

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About BHR Braemar Hotels & Resorts Inc.

Braemar Hotels & Resorts Inc is a real estate investment trust company that invests in high revenue per available room, or RevPAR, luxury hotels and resorts. The firm operates in various U.S. states such as California, Texas, Washington, Philadelphia, Florida, and Illinois as well as Washington, D.C. and St. Thomas, U.S. Virgin Islands. The company operates through its direct hotel investment segment of the hotel lodging industry. Its revenue streams include rooms, food and beverage, and other. The firm's hotels operate under various brands, such as Marriott, Hilton, Courtyard, and, among others.

Share on Social Networks: